New trial
DLL3-Targeting Theranostic Agent Explored in High-grade Neuroendocrine Cancers
- Trial ID
- NCT06941480 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 7 Locations
- Published in
- New in Oncology - May 7, 2025
Memorial Sloan Kettering is evaluating the safety of 177Lu-DTPA-SC16.56 for relapsed, advanced small-cell lung and neuroendocrine prostate cancers. This study leverages PET/CT imaging to determine the theranostic potential of DLL3-targeted treatment in these aggressive malignancies.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings